I posted some scenarios when the “more than $500
Post# of 36514
But I believe Joe will be able to upsell that amount based on investors’ risk appetites leveraged against the potential upside of NGIO’s various projects.
I also believe there will be some level of increase based on progress between when the valuation was completed and when the IPO prices/executes. If there is clear pre-clinical success and an IND, that could add substantial value, IMO.
I sure hope the events Joe was planning for the time between the call announcement and the actual call come together. It would be huge to have a time frame for the IPO and all the pricing/cap structure before the call so we can prep Qs and to increase the size of the interested audience.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)